Kinnate Biopharma (KNTE) Stock Forecast, Price Target & Predictions

KNTE Stock Forecast

Kinnate Biopharma stock forecast is as follows: an average price target of $30.00 (represents a 1032.08% upside from KNTE’s last price of $2.65) and a rating consensus of 'Hold', based on 3 wall street analysts offering a 1-year stock forecast.

KNTE Price Target

The average price target for Kinnate Biopharma (KNTE) is $30.00 based on 1-year price targets from 3 Wall Street analysts in the past 3 months, with a price target range of $30.00 to $30.00. This represents a potential 1032.08% upside from KNTE's last price of $2.65.

KNTE Analyst Ratings

Hold

According to 3 Wall Street analysts, Kinnate Biopharma's rating consensus is 'Hold'. The analyst rating breakdown for KNTE stock is 0 'Strong Buy' (0.00%), 1 'Buy' (33.33%), 2 'Hold' (66.67%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).

Kinnate Biopharma Price Target by Analyst

Date	Analyst	Company	Price Target	Price when Published	Price Target/Price when Published	Price Target/Last Closing Price
May 18, 2022	Christopher Raymond	Piper Sandler	$30.00	$9.96	201.20%	1032.08%

The latest Kinnate Biopharma stock forecast, released on May 18, 2022 by Christopher Raymond from Piper Sandler, set a price target of $30.00, which represents a 201.20% increase from the stock price at the time of the forecast ($9.96), and a 1032.08% increase from KNTE last price ($2.65).

Kinnate Biopharma Price Target by Period

	1M	3M	12M
# Anlaysts	-	-	-
Avg Price Target	-	-	-
Last Closing Price	$2.65	$2.65	$2.65
Upside/Downside	-100.00%	-100.00%	-100.00%

In the current month, the average price target of Kinnate Biopharma stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Kinnate Biopharma's last price of $2.65. This month's average price target is down NaN% compared to last quarter, and down NaN% compared to last year.

Analyst Ratings Upgrades/Downgrades

Date	Company	Previous Rating	New Rating	Rating Change
Sep 19, 2023	Piper Sandler	Overweight	Neutral	Downgrade
Sep 19, 2023	Wedbush		Neutral	Downgrade
May 18, 2022	Piper Sandler	Overweight	Overweight	Hold
Mar 29, 2022	William Blair	Outperform	Outperform	Hold

Kinnate Biopharma's last stock rating was published by Piper Sandler on Sep 19, 2023. The company Downgrade its KNTE rating from "Overweight" to "Neutral".

Kinnate Biopharma Financial Forecast

Kinnate Biopharma Revenue Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23
Revenue	-	-	-	-	-	-	-	-	-
Avg Forecast	-	-	-	-	-	-	-	-	-
High Forecast	-	-	-	-	-	-	-	-	-
Low Forecast	-	-	-	-	-	-	-	-	-
# Analysts	-	-	-	-	-	-	-	-	-
Surprise %	-	-	-	-	-	-	-	-	-

Kinnate Biopharma's average Quarter revenue forecast for undefined based on undefined analysts is $NaN, with a low forecast of $NaN, and a high forecast of $NaN. KNTE's average Quarter revenue forecast represents a NaN% decrease compared to the company's last Quarter revenue of $NaN (undefined).

Kinnate Biopharma EBITDA Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23
# Analysts	-	-	-	-	-	-	-	-	-
EBITDA	-	-	-	-	-	-	-	-	-
Avg Forecast	-	-	-	-	-	-	-	-	-
High Forecast	-	-	-	-	-	-	-	-	-
Low Forecast	-	-	-	-	-	-	-	-	-
Surprise %	-	-	-	-	-	-	-	-	-

undefined analysts predict KNTE's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Kinnate Biopharma's previous annual EBITDA (undefined) of $NaN.

Kinnate Biopharma Net Income Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23
# Analysts	-	-	-	-	-	-	-	-	-
Net Income	-	-	-	-	-	-	-	-	-
Avg Forecast	$-8.95M	$-8.95M	$-12.25M	$-12.25M	$-9.42M	$-13.67M	$-13.67M	$-13.67M	$-20.03M
High Forecast	$-8.95M	$-8.95M	$-12.25M	$-12.25M	$-9.42M	$-13.67M	$-13.67M	$-11.01M	$-16.47M
Low Forecast	$-8.95M	$-8.95M	$-12.25M	$-12.25M	$-9.42M	$-13.67M	$-13.67M	$-16.32M	$-22.25M
Surprise %	-	-	-	-	-	-	-	-	-

Kinnate Biopharma's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. KNTE's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).

Kinnate Biopharma SG&A Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23
# Analysts	-	-	-	-	-	-	-	-	-
SG&A	-	-	-	-	-	-	-	-	-
Avg Forecast	-	-	-	-	-	-	-	-	-
High Forecast	-	-	-	-	-	-	-	-	-
Low Forecast	-	-	-	-	-	-	-	-	-
Surprise %	-	-	-	-	-	-	-	-	-

Kinnate Biopharma's average Quarter SG&A projection for undefined is $NaN, based on undefined Wall Street analysts, with a range of $NaN to $NaN. The forecast indicates a NaN% fall compared to KNTE last annual SG&A of $NaN (undefined).

Kinnate Biopharma EPS Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23
# Analysts	-	-	-	-	-	-	-	-	-
EPS	-	-	-	-	-	-	-	-	-
Avg Forecast	$-0.19	$-0.19	$-0.26	$-0.26	$-0.20	$-0.29	$-0.29	$-0.29	$-0.42
High Forecast	$-0.19	$-0.19	$-0.26	$-0.26	$-0.20	$-0.29	$-0.29	$-0.23	$-0.35
Low Forecast	$-0.19	$-0.19	$-0.26	$-0.26	$-0.20	$-0.29	$-0.29	$-0.35	$-0.47
Surprise %	-	-	-	-	-	-	-	-	-

According to undefined Wall Street analysts, Kinnate Biopharma's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to KNTE previous annual EPS of $NaN (undefined).

Kinnate Biopharma Peer Comparison by Price Target

Ticker	Company	Last Closing Price	Avg Price Target	Upside/Downside	Avg Rating
PASG	Passage Bio	$0.67	$6.00	795.52%	Buy
KROS	Keros Therapeutics	$18.00	$102.00	466.67%	Buy
CCCC	C4 Therapeutics	$4.05	$20.00	393.83%	Buy
IPSC	Century Therapeutics	$1.17	$5.00	327.35%	Buy
LRMR	Larimar Therapeutics	$4.32	$17.00	293.52%	Buy
SLRN	Acelyrin	$3.50	$10.50	200.00%	Buy
KZR	Kezar Life Sciences	$6.52	$17.50	168.40%	Buy
ERAS	Erasca	$2.63	$6.00	128.14%	Buy
STOK	Stoke Therapeutics	$12.10	$26.50	119.01%	Buy
BOLT	Bolt Biotherapeutics	$0.54	$1.00	85.19%	Hold
DSGN	Design Therapeutics	$6.25	$9.67	54.72%	Buy
EWTX	Edgewise Therapeutics	$30.17	$46.25	53.30%	Buy
KRON	Kronos Bio	$0.96	$1.00	4.17%	Buy
PALI	Palisade Bio	$1.90	$1.50	-21.05%	Buy

KNTE Forecast FAQ

Is Kinnate Biopharma a good buy?

No, according to 3 Wall Street analysts, Kinnate Biopharma (KNTE) is considered a 'Hold'. The rating consensus is based on 0 'Strong Buy' and 1 'Buy' recommendations, accounting for 33.33% of KNTE's total ratings.

What is KNTE's price target?

Kinnate Biopharma (KNTE) average price target is $30 with a range of $30 to $30, implying a 1032.08% from its last price of $2.65. The data is based on 3 Wall Street analysts who provided a twelve-month price target estimate in the last three months.

Will Kinnate Biopharma stock go up soon?

According to Wall Street analysts' prediction for KNTE stock, the company can go up by 1032.08% (from the last price of $2.65 to the average price target of $30), up by 1032.08% based on the highest stock price target, and up by 1032.08% based on the lowest stock price target.

Can Kinnate Biopharma stock reach $4?

KNTE's average twelve months analyst stock price target of $30 supports the claim that Kinnate Biopharma can reach $4 in the near future.

What are Kinnate Biopharma's analysts' financial forecasts?

Kinnate Biopharma's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $0 (high $0, low $0), average EBITDA is $0 (high $0, low $0), average net income is $-50.423M (high $-47.766M, low $-53.08M), average SG&A $0 (high $0, low $0), and average EPS is $-1.07 (high $-1.014, low $-1.126). KNTE's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $0 (high $0, low $0), average EBITDA is $0 (high $0, low $0), average net income is $-42.412M (high $-42.412M, low $-42.412M), average SG&A $0 (high $0, low $0), and average EPS is $-0.9 (high $-0.9, low $-0.9).